A multidisciplinary approach combining biochemical, cell biology, microbiology techniques as well murine models of P. aeruginosa acute lung infections were used to demonstrate antinfective and anti-inflammatory properties of the new peptides; moreover, preclinical testing was performed to establish their safety profiles and therapeutic dosages. Their efficacy in reducing lung bacterial burden in murine models upon intratracheal instillation was shown, without causing lung epithelial injury, on the contrary, favouring re-epithelialization of the tissue. Researchers indicate high potential to develop AMP-based pharmaceutical formulations against P. aeruginosa lung infection in CF by local administration. Further studies will be necessary to identify best strategies for pulmonary release of the peptides at effective concentrations.